Filing Flows

Filing Flows › BridgeBio Pharma (BBIO) › Next earnings date

BridgeBio Pharma (BBIO) earnings: beat the estimate

BridgeBio Pharma (BBIO) reported on Oct 29, 2026 and beat the EPS estimate: −$0.42 against −$0.56 (+24.6%). Revenue was $353M for Q3 2026, +193% year over year. It beat the EPS estimate in 40% of the quarters on record.

Last result+24.6% vs estimate
Beat rate40%

The last report

BridgeBio Pharma reported revenue of $353M for the third quarter 2026 (+193% Y/Y), net loss $60.5M: Net product revenue $253M, License and services revenue $79.3M, Royalty revenue $20.5M. How it makes money → · Every quarter →

BridgeBio Pharma: EPS against the estimate, last 5 reportsBridgeBio Pharma: EPS against the estimate, last 5 reportsEstimateReported−$0.78−$0.72Oct 25−$0.62−$0.94Feb 26−$0.62−$0.84May 26−$0.58−$0.78Aug 26−$0.56−$0.42Oct 26
Latest (Oct 26): Estimate −$0.56, Reported −$0.42.

BridgeBio Pharma's latest quarter

BridgeBio Pharma, Q3 2026: revenue $353M (+193% year over year), operating margin -3.3%, net loss $60.5M, operating cash flow −$44.2M. The chart follows the revenue to costs, profit and cash.

Questions

Did BridgeBio Pharma beat earnings?

BridgeBio Pharma (BBIO) reported on Oct 29, 2026 and beat the EPS estimate: −$0.42 against −$0.56 (+24.6%).

When does BBIO report earnings?

The next date is not set yet.

Does BridgeBio Pharma usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.